Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

Effect of 600 mg Dalcetrapib Administration on Plasma HDL Stein EA, et al. Eur Heart J. 2010;31(4):480‐488. Stein E et al. Eur Heart J. 2010;31:480-488. Increase HDL = 32% Dalcetrapib Placebo 54
The dal-HEART Program: Dalcetrapib HDL Evaluation, Atherosclerosis, and Reverse Cholesterol Transport dal-VESSEL 450 patients with CHD or CHD risk equivalent To evaluate the effect of dalcetrapib on endothelial function and BP, measured by FMD and ABPM dal-PLAQuE 130 patients with CHD To evaluate the effect of dalcetrapib on inflammation, plaque size, and burden, measured by PET/CT and MRI scans dal-PLAQUE 2 900 patients with CAD To evaluate the effect of dalcetrapib on CVD progression, assessed by IVUS and carotid Bmode ultrasound dal- ACUTE 300 patients with ACS To evaluate the safety and efficacy of dalcetrapib in patients hospitalized for ACS. Treatment initiated within 1 week a nd last for 20 weeks ACS=acute coronary syndrome; FMD=flow-mediated dilation; ABPM=ambulatory blood pressure monitoring; CAD=coronary artery disease; IVUS=intravascular ultrasound; PET=positron emission tomography; CT=computed tomography; MRI=magnetic resonance Schwartz GG, et al. Amer. Heart J. 2009;158:896-901 55
Page 1 and 2:
Treating Lipid Abnormalities Beyond
Page 3 and 4: THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7 and 8: Lipoprotein Metabolism in Patients
Page 9 and 10: LOW HDL-C AS A RESIDUAL RISK FACTOR
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31 and 32: HDL Targeted Therapies: Niacin 1. D
Page 33 and 34: HATS: Angiographic and Clinical End
Page 35 and 36: � � Aim High randomized 3414 pa
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43 and 44: Preβ-HDL Enriched Plasma Obtained
Page 45 and 46: The Reduction in Plaque was Greater
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53: CETP Inhibitors CETP Torcetrapib Da
Page 57 and 58: LDL (mg/dL) Define Trial: Effect of
Page 59: FUTURE THERAPY FOR CARDIOVASCULAR D
show all

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Create successful ePaper yourself

Delete template?

Save as template?